ArticlePharmacoEconomics1992
Recombinant granulocyte colony-stimulating factor (rG-CSF): pharmacoeconomic considerations in chemotherapy-induced neutropenia.
Article in PharmacoEconomics, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Cost analysis of 2 empiric antibacterial regimens containing glycopeptides for the treatment of febrile neutropenia in patients with acute leukaemia.PharmacoEconomics · 1999Trial
- Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma.PharmacoEconomics · 1994Trial
- Review
- Challenges to the economic evaluation of new biotechnological interventions in healthcare.PharmacoEconomics · 1999Article
- Autologous peripheral blood progenitor-cell transplantation versus autologous bone marrow transplantation for adults and children with non-leukaemic malignant disease. A randomised economic study.PharmacoEconomics · 1997Article
- Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia.PharmacoEconomics · 1996Article
- Review
- Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.Drugs · 1994Review
- Using cost-effectiveness analysis for formulary decision making: from theory into practice.PharmacoEconomics · 1994Article
- The costs of treating febrile neutropenia in patients with malignant blood disorders.PharmacoEconomics · 1994Article
- Economic study of neutropenia induced by myelotoxic chemotherapy.Pharmacy world & science : PWS · 1994Article
- Cost-effective use of autologous bone marrow transplantation: few answers, many questions, and suggestions for future assessments.PharmacoEconomics · 1994Review
- Colony-stimulating factors. Present status and future potential.PharmacoEconomics · 1994Review
- Idarubicin: a pharmacoeconomic evaluation of its use in adult patients with acute myeloid leukaemia.PharmacoEconomics · 1993Review
- Economic evaluation of pharmaceuticals: a European perspective.PharmacoEconomics · 1993Review
- Determinants of hospital drug expenditures in Western Europe.PharmacoEconomics · 1993Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant granulocyte colony-stimulating factor (rG-CSF) therapy is associated with a dose-proportional reduction in the frequency, duration and severity of neutropenia associated with cytotoxic chemotherapy. This is associated with a decrease in the incidence of infection, with subsequent reductions in the number of hospitalisations, days of hospitalisation and antibiotic requirements. These effects produce marked reductions in costs, and could contribute substantially towards offsetting the costs of rG-CSF, although the magnitude of the savings will vary between institutions and with the chemotherapy regimen used. Other benefits include a reduction in the frequency and severity of mucositis, and an improved patient quality of life. However, further research is required to evaluate other potentially important considerations including the targeting of specific patient populations (e.g. those receiving regimens with a curative intent), and additional improvements in patient quality of life and, perhaps, mortality. Thus, although specific pharmacoeconomic analyses are limited, preliminary evidence indicates that rG-CSF, administered prior to the onset of neutropenia in patients receiving cytotoxic chemotherapy, can provide cost reductions both from an institutional and a payor perspective, with even greater potential savings from a societal viewpoint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.